Targeting blockage of stat3 in hepatocellular carcinoma cells augments nk cell functions via reverse hepatocellular carcinoma-induced immune suppression

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2885-2896

  Sun, Xiaoxia ^a   Sui, Qiangjun ^a   Zhang, Cai ^a   Tian, Zhigang ^a,b   Zhang, Jian ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOKINE; INTERFERON; INTERLEUKIN 10; NATURAL KILLER CELL RECEPTOR NKG2D; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR RECOGNITION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SUPERNATANT; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; LIGANDS; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; STAT3 TRANSCRIPTION FACTOR;

EID: 84890500784     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1087     Document Type: Article

References (39)

1. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012;40:1733-47.
2. Ito K, Stannard K, Gabutero E, Clark AM, Neo SY, Onturk S, et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer metastasis reviews 2012;31: 763-78.
3. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011;121:3609-22.
4. Ihara S, Kida H, Arase H, Tripathi LP, Chen YA, Kimura T, et al. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res 2012;72:2990-9.
5. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008;129: 428-37.
6. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for theNK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 2003;100:4120-5.
7. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012;72:1407-15.
8. Gupta M, Han JJ, Stenson M, Maurer M, Wellik L, Hu G, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: A mechanism of aberrant JAK2 activation. Blood 2012;119:2844-53.
9. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012;109:9623-8.
10. Luwor RB, Baradaran B, Taylor LE, Iaria J, Nheu TV, Amiry N, et al. Targeting Stat3 and Smad7 to restore TGF-beta cytostatic regulation of tumor cells in vitro and in vivo. Oncogene 2013;32:2433-41.
11. Zhang X, Zhang J, Wang L, Wei H, Tian Z. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007;7:149.
12. Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z, et al. JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment. Cancer Biol Ther 2008;7:1243-9.
13. Sun X, Zhang J, Wang L, Tian Z. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy- ODN. Cancer Lett 2008;262:201-13.
14. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med 2004;10:48-54.
15. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
16. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 2008;180:2089-98.
17. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Med 2005;11: 1314-21.
18. Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005;175:4338-46.
19. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, et al. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 2010;16:2550-61.
20. Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Diaz FlaqueMC, et al. Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells. J Immunol 2012;189: 1162-72.
21. Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, et al. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res 2011;71:1615-26.
22. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 2003;100: 4138-43.
23. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008;27:5944-58.
24. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008;9:503-10.
25. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity 2006;24:249-57.
26. Coulouarn C, Corlu A, Glaise D, Guenon I, ThorgeirssonSS, Clement B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012;72:2533-42.
27. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressivecytokines and apoptosis resistance. Molecular Immunol 2007;44:2850-9.
28. Teruel A, Romero M, Cacalano NA, Head C, Jewett A. Potential contribution of naive immune effectors to oral tumor resistance: role in synergistic induction of VEGF, IL-6, and IL-8 secretion. Cancer Immunol, Immunother 2008;57:359-66.
29. Lopez MN, Pesce B, Kurte M, Perez C, Segal G, Roa J, et al.A synthetic peptide homologous to IL-10 functional domain induces monocyte differentiation to TGF-beta+ tolerogenic dendritic cells. Immunobiology 2011;216:1117-26.
30. Donkor MK, Sarkar A, Li MO. Tgf-beta1 produced by activated CD4 T Cells Antagonizes T Cell Surveillance of Tumor Development. Oncoimmunology 2012;1:162-71.
31. Shimizu H, Nakagami H, Tsukamoto I, Morita S, Kunugiza Y, Tomita T, et al. NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene ther 2006;13:933-41.
32. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficientmice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008;28:571-80.
33. Zocchi MR, Catellani S, Canevali P, Tavella S, Garuti A, Villaggio B, et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood 2012;119:1479-89.
34. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008;68:3835-43.
35. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012;189:1360-71.
36. Yoon S, Woo SU, Kang JH, Kim K, Kwon MH, Park S, et al. STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells. Autophagy 2010;6: 1125-38.
37. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011;208: 1989-2003.
38. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, SanmamedMF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011;17:2619-27.
39. Khallouf H, Marten A, Serba S, Teichgraber V, Buchler MW, Jager D, et al. 5-Fluorouracil and interferon-alpha immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother 2012;35: 245-53.